Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02546661
Title	Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY)
Acronym	BISCAY
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	invasive bladder transitional cell carcinoma
Therapies	Danvatirsen + Durvalumab Durvalumab + Selumetinib Fexagratinib Durvalumab + Olaparib Durvalumab Durvalumab + Fexagratinib Durvalumab + Vistusertib Adavosertib + Durvalumab
Age Groups:	adult \| senior
Covered Countries	USA \| GBR \| FRA \| ESP \| CAN